Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Case Report: A novel method of needle-free transseptal puncture.
Lee CC, Chao CA, Chang SH, Chen CK, Chen YS, Lin CE, Jeng TP, Yu CC. Lee CC, et al. Among authors: chao ca. Front Cardiovasc Med. 2024 Dec 3;11:1493240. doi: 10.3389/fcvm.2024.1493240. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39691495 Free PMC article.
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ, Wardell SE, Baker JG, Desautels TK, Baldi R, Chao CA, Heetderks KA, Bae Y, Xiong R, Tonetti DA, Gutgesell LM, Zhao J, Sorrentino JA, Thompson DA, Bisi JE, Strum JC, Thatcher GRJ, Norris JD. Andreano KJ, et al. Among authors: chao ca. Breast Cancer Res Treat. 2020 Apr;180(3):635-646. doi: 10.1007/s10549-020-05575-9. Epub 2020 Mar 4. Breast Cancer Res Treat. 2020. PMID: 32130619 Free PMC article.
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
Wardell SE, Yllanes AP, Chao CA, Bae Y, Andreano KJ, Desautels TK, Heetderks KA, Blitzer JT, Norris JD, McDonnell DP. Wardell SE, et al. Among authors: chao ca. Breast Cancer Res Treat. 2020 Feb;179(3):769. doi: 10.1007/s10549-019-05498-0. Breast Cancer Res Treat. 2020. PMID: 31734822 Free PMC article.
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
Wardell SE, Yllanes AP, Chao CA, Bae Y, Andreano KJ, Desautels TK, Heetderks KA, Blitzer JT, Norris JD, McDonnell DP. Wardell SE, et al. Among authors: chao ca. Breast Cancer Res Treat. 2020 Jan;179(1):67-77. doi: 10.1007/s10549-019-05454-y. Epub 2019 Sep 27. Breast Cancer Res Treat. 2020. PMID: 31562570 Free PMC article.
18 results